GlobeNewswire Inc.··NaAvalo Therapeutics Raises $375M to Advance Hidradenitis Suppurativa Treatment
Avalo Therapeutics prices $375M offering of 19.73M shares at $17.75 each to fund Phase 3 development of hidradenitis suppurativa treatment abdakibart, closing May 7, 2026.
AVTXPhase 3 clinical trialpublic offering